Natural Product Inhibitors of Ubiquitin Conjugation and Deconjugation

Wilfried Hess, Muhammad Mukram Mohamed Mackeen, Holger B. Kramer

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The ubiquitin–proteasome system has been recognized as fundamental toward protein turnover in eukaryotic cells. The system comprises the ubiquitin conjugation machinery consisting of an enzyme cascade of E1, E2, and E3 enzymes, the deubiquitinases (DUBs) and the proteasome, a multisubunit protease complex acting through an N-terminal threonine protease mechanism. A number of natural product inhibitors of the proteasome have been studied in detail and these inhibitors and their derivatives have been highly valuable in developing our understanding of this system. These efforts culminated in the successful development of bortezomib as a pharmacological agent used clinically as a cancer therapeutic in the treatment of multiple myeloma. This review is focused on natural product inhibitors of the enzymes involved in intracellular ubiquitin conjugation (ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2, ubiquitin ligase E3) and ubiquitin deconjugation (DUBs). Members of both of these enzyme systems have been proposed as pharmacological targets for cancer therapy and several other diseases. Furthermore compounds with activities toward enzymes from the analogous ubiquitin-like (Ubl) protein families have been identified for SUMO and NEDD8. To date natural product inhibitors have been described for members of each of these protein families and were isolated from plant, fungal, animal, and microbial sources. Insights into the mechanism of action of natural products and their derivatives will enhance our understanding of this complex system and will improve our ability to rationally design novel inhibitors. The increased availability of assays and research tools for the study of protein ubiquitination, deubiquitination, and Ubl proteins will contribute to the discovery of more potent and selective compounds. We expect that these studies will stimulate development of further potential pharmacological agents in this area.

Original languageEnglish
Title of host publicationStudies in Natural Products Chemistry
PublisherElsevier B.V.
Pages207-242
Number of pages36
Volume49
DOIs
Publication statusPublished - 2016

Publication series

NameStudies in Natural Products Chemistry
Volume49
ISSN (Print)15725995

Fingerprint

Ubiquitin
Biological Products
Ubiquitins
Pharmacology
Enzymes
Peptide Hydrolases
Ubiquitin-Activating Enzymes
Ubiquitin-Conjugating Enzymes
Derivatives
Proteins
Proteasome Inhibitors
Ubiquitin-Protein Ligases
Ubiquitination
Enzyme activity
Eukaryotic Cells
Enzyme Inhibitors
Proteasome Endopeptidase Complex
Threonine
Multiple Myeloma
Machinery

Keywords

  • Deubiquitinase and ubiquitin-like protein
  • Ubiquitin conjugation
  • Ubiquitin deconjugation
  • Ubiquitin–proteasome system

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry

Cite this

Hess, W., Mohamed Mackeen, M. M., & Kramer, H. B. (2016). Natural Product Inhibitors of Ubiquitin Conjugation and Deconjugation. In Studies in Natural Products Chemistry (Vol. 49, pp. 207-242). (Studies in Natural Products Chemistry; Vol. 49). Elsevier B.V.. https://doi.org/10.1016/B978-0-444-63601-0.00006-5

Natural Product Inhibitors of Ubiquitin Conjugation and Deconjugation. / Hess, Wilfried; Mohamed Mackeen, Muhammad Mukram; Kramer, Holger B.

Studies in Natural Products Chemistry. Vol. 49 Elsevier B.V., 2016. p. 207-242 (Studies in Natural Products Chemistry; Vol. 49).

Research output: Chapter in Book/Report/Conference proceedingChapter

Hess, W, Mohamed Mackeen, MM & Kramer, HB 2016, Natural Product Inhibitors of Ubiquitin Conjugation and Deconjugation. in Studies in Natural Products Chemistry. vol. 49, Studies in Natural Products Chemistry, vol. 49, Elsevier B.V., pp. 207-242. https://doi.org/10.1016/B978-0-444-63601-0.00006-5
Hess W, Mohamed Mackeen MM, Kramer HB. Natural Product Inhibitors of Ubiquitin Conjugation and Deconjugation. In Studies in Natural Products Chemistry. Vol. 49. Elsevier B.V. 2016. p. 207-242. (Studies in Natural Products Chemistry). https://doi.org/10.1016/B978-0-444-63601-0.00006-5
Hess, Wilfried ; Mohamed Mackeen, Muhammad Mukram ; Kramer, Holger B. / Natural Product Inhibitors of Ubiquitin Conjugation and Deconjugation. Studies in Natural Products Chemistry. Vol. 49 Elsevier B.V., 2016. pp. 207-242 (Studies in Natural Products Chemistry).
@inbook{865c4d5cdb3a4656bf1735540d366c5a,
title = "Natural Product Inhibitors of Ubiquitin Conjugation and Deconjugation",
abstract = "The ubiquitin–proteasome system has been recognized as fundamental toward protein turnover in eukaryotic cells. The system comprises the ubiquitin conjugation machinery consisting of an enzyme cascade of E1, E2, and E3 enzymes, the deubiquitinases (DUBs) and the proteasome, a multisubunit protease complex acting through an N-terminal threonine protease mechanism. A number of natural product inhibitors of the proteasome have been studied in detail and these inhibitors and their derivatives have been highly valuable in developing our understanding of this system. These efforts culminated in the successful development of bortezomib as a pharmacological agent used clinically as a cancer therapeutic in the treatment of multiple myeloma. This review is focused on natural product inhibitors of the enzymes involved in intracellular ubiquitin conjugation (ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2, ubiquitin ligase E3) and ubiquitin deconjugation (DUBs). Members of both of these enzyme systems have been proposed as pharmacological targets for cancer therapy and several other diseases. Furthermore compounds with activities toward enzymes from the analogous ubiquitin-like (Ubl) protein families have been identified for SUMO and NEDD8. To date natural product inhibitors have been described for members of each of these protein families and were isolated from plant, fungal, animal, and microbial sources. Insights into the mechanism of action of natural products and their derivatives will enhance our understanding of this complex system and will improve our ability to rationally design novel inhibitors. The increased availability of assays and research tools for the study of protein ubiquitination, deubiquitination, and Ubl proteins will contribute to the discovery of more potent and selective compounds. We expect that these studies will stimulate development of further potential pharmacological agents in this area.",
keywords = "Deubiquitinase and ubiquitin-like protein, Ubiquitin conjugation, Ubiquitin deconjugation, Ubiquitin–proteasome system",
author = "Wilfried Hess and {Mohamed Mackeen}, {Muhammad Mukram} and Kramer, {Holger B.}",
year = "2016",
doi = "10.1016/B978-0-444-63601-0.00006-5",
language = "English",
volume = "49",
series = "Studies in Natural Products Chemistry",
publisher = "Elsevier B.V.",
pages = "207--242",
booktitle = "Studies in Natural Products Chemistry",

}

TY - CHAP

T1 - Natural Product Inhibitors of Ubiquitin Conjugation and Deconjugation

AU - Hess, Wilfried

AU - Mohamed Mackeen, Muhammad Mukram

AU - Kramer, Holger B.

PY - 2016

Y1 - 2016

N2 - The ubiquitin–proteasome system has been recognized as fundamental toward protein turnover in eukaryotic cells. The system comprises the ubiquitin conjugation machinery consisting of an enzyme cascade of E1, E2, and E3 enzymes, the deubiquitinases (DUBs) and the proteasome, a multisubunit protease complex acting through an N-terminal threonine protease mechanism. A number of natural product inhibitors of the proteasome have been studied in detail and these inhibitors and their derivatives have been highly valuable in developing our understanding of this system. These efforts culminated in the successful development of bortezomib as a pharmacological agent used clinically as a cancer therapeutic in the treatment of multiple myeloma. This review is focused on natural product inhibitors of the enzymes involved in intracellular ubiquitin conjugation (ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2, ubiquitin ligase E3) and ubiquitin deconjugation (DUBs). Members of both of these enzyme systems have been proposed as pharmacological targets for cancer therapy and several other diseases. Furthermore compounds with activities toward enzymes from the analogous ubiquitin-like (Ubl) protein families have been identified for SUMO and NEDD8. To date natural product inhibitors have been described for members of each of these protein families and were isolated from plant, fungal, animal, and microbial sources. Insights into the mechanism of action of natural products and their derivatives will enhance our understanding of this complex system and will improve our ability to rationally design novel inhibitors. The increased availability of assays and research tools for the study of protein ubiquitination, deubiquitination, and Ubl proteins will contribute to the discovery of more potent and selective compounds. We expect that these studies will stimulate development of further potential pharmacological agents in this area.

AB - The ubiquitin–proteasome system has been recognized as fundamental toward protein turnover in eukaryotic cells. The system comprises the ubiquitin conjugation machinery consisting of an enzyme cascade of E1, E2, and E3 enzymes, the deubiquitinases (DUBs) and the proteasome, a multisubunit protease complex acting through an N-terminal threonine protease mechanism. A number of natural product inhibitors of the proteasome have been studied in detail and these inhibitors and their derivatives have been highly valuable in developing our understanding of this system. These efforts culminated in the successful development of bortezomib as a pharmacological agent used clinically as a cancer therapeutic in the treatment of multiple myeloma. This review is focused on natural product inhibitors of the enzymes involved in intracellular ubiquitin conjugation (ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2, ubiquitin ligase E3) and ubiquitin deconjugation (DUBs). Members of both of these enzyme systems have been proposed as pharmacological targets for cancer therapy and several other diseases. Furthermore compounds with activities toward enzymes from the analogous ubiquitin-like (Ubl) protein families have been identified for SUMO and NEDD8. To date natural product inhibitors have been described for members of each of these protein families and were isolated from plant, fungal, animal, and microbial sources. Insights into the mechanism of action of natural products and their derivatives will enhance our understanding of this complex system and will improve our ability to rationally design novel inhibitors. The increased availability of assays and research tools for the study of protein ubiquitination, deubiquitination, and Ubl proteins will contribute to the discovery of more potent and selective compounds. We expect that these studies will stimulate development of further potential pharmacological agents in this area.

KW - Deubiquitinase and ubiquitin-like protein

KW - Ubiquitin conjugation

KW - Ubiquitin deconjugation

KW - Ubiquitin–proteasome system

UR - http://www.scopus.com/inward/record.url?scp=84999780341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999780341&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-63601-0.00006-5

DO - 10.1016/B978-0-444-63601-0.00006-5

M3 - Chapter

AN - SCOPUS:84999780341

VL - 49

T3 - Studies in Natural Products Chemistry

SP - 207

EP - 242

BT - Studies in Natural Products Chemistry

PB - Elsevier B.V.

ER -